| First Author | El-Sitt S | Year | 2019 |
| Journal | Front Neurol | Volume | 10 |
| Pages | 128 | PubMed ID | 30837943 |
| Mgi Jnum | J:276090 | Mgi Id | MGI:6313848 |
| Doi | 10.3389/fneur.2019.00128 | Citation | El-Sitt S, et al. (2019) Developmental Comparison of Ceramide in Wild-Type and Cln3 (Deltaex7/8) Mouse Brains and Sera. Front Neurol 10:128 |
| abstractText | CLN3 disease is a neurodevelopmental disease leading to early visual failure, motor decline, and death. CLN3 pathogenesis has been linked to dysregulation of ceramide, a key intracellular messenger impacting various biological functions. Ceramide is upregulated in brains of CLN3 patients and activates apoptosis. Ceramide levels over the lifespan of WT and Cln3 (Deltaex7/8) mice were measured using the DGK assay. Ceramide subspecies were determined by LC-MS. Ceramide synthesis enzymes and pre- and post-synaptic mRNA expression was measured in Cln3 (Deltaex7/8) and normal mouse brains. Neuronal cell death was established by PARP cleavage and Caspases 3/6/9 and cytochrome C mRNA expression in Cln3 (Deltaex7/8) and normal mouse brains. In WT mouse, a ceramide peak was noted at 3 weeks of age. The absence of this peak in Cln3 (Deltaex7/8) mice might be related to early disease pathogenesis. Increase of ceramide in Cln3 (Deltaex7/8) mouse brain at 24 weeks of age precedes neuronal apoptosis. The correlation between serum and brain ceramide in WT mice, and dysregulation of ceramide in serum and brain of Cln3 (Deltaex7/8) mice, and the significant increase in ceramide in Cln3 (Deltaex7/8) mouse brains and sera argue for use of easily accessible serum ceramide levels to track response to novel therapies in human CLN3 disease. |
